Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for moyamoya disease 3 has been reported in the published literature.
No clinical trials have been registered for moyamoya disease 3.
6 publications have been identified in PubMed for moyamoya disease 3. Research spans Diagnostic / Biomarker (17%), Review / Meta-Analysis (17%), and Case Report / Case Series (17%).
Zhu Y (2025). [PMID: 38845225](https://pubmed.ncbi.nlm.nih.gov/38845225/). *Neural regeneration research*. [Review / Meta-Analysis]
Imai R (2025). [PMID: 39944439](https://pubmed.ncbi.nlm.nih.gov/39944439/). *Cureus*. [Diagnostic / Biomarker]
Uchino H (2025). [PMID: 40301050](https://pubmed.ncbi.nlm.nih.gov/40301050/). *Neurologia medico-chirurgica*. [Gene Therapy / Novel Therapeutics]
Manara R (2025). [PMID: 41291755](https://pubmed.ncbi.nlm.nih.gov/41291755/). *Orphanet journal of rare diseases*. [Epidemiology / Natural History]
Shivashankar T (2025). [PMID: 41180760](https://pubmed.ncbi.nlm.nih.gov/41180760/). *Annals of medicine and surgery (2012)*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Nov 4, 2026, 4:23 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
AI-curated news mentioning moyamoya disease 3
Updated Oct 8, 2026
A comparative MRI study reveals significant differences in intracranial artery and brain impairment between pediatric and adult moyamoya disease patients. This research enhances understanding of disease progression and may inform tailored treatment approaches.
A case study highlights the occurrence of Fregoli syndrome in an adolescent diagnosed with Moyamoya disease. This research adds to the understanding of the neurological implications associated with Moyamoya disease.
Recent research highlights the role of lipid metabolism in moyamoya disease, suggesting potential therapeutic implications through vascular remodeling. This emerging evidence could inform future treatment strategies for this rare cerebrovascular condition.